Bristol Myers Squibb Gains Expanded EU Approval for CAR-T Therapy Breyanzi

The European Commission has granted Bristol Myers Squibb (NYSE: BMY) an expanded approval for its CAR-T cell therapy, Breyanzi, the biopharmaceutical company announced on Friday.

Key Details of the Approval:

• New Indication: Breyanzi is now approved for treating adults with relapsed or refractory follicular lymphoma who have undergone at least two prior systemic therapies.
• Treatment Mechanism:
  • Breyanzi is a CAR-T cell therapy, which involves genetically modifying a patient’s immune cells to recognize and attack cancer cells.
• Significance:
  • The expanded approval broadens access to a cutting-edge treatment option for patients with limited alternatives.
  • The decision follows clinical evidence demonstrating Breyanzi’s efficacy in patients who did not respond to prior treatments or experienced relapse.

This approval reinforces Bristol Myers Squibb’s leadership in the cell therapy space, potentially boosting its market presence in Europe while offering new hope for lymphoma patients.